Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 301

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 301
---
 exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The following table presents information about the Company’s significant suppliers:

| ​        
 ​        | ​ 
 ​ |                       ​ 
      For the Year Ended | ​ |    ​ | ​ 
 ​ |                     ​ 
                     ​ | ​ 
 ​ |    ​ 
    ​ | ​ |
|:---------|:--|------------------------:|:--|-----:|:--|----------------------:|:--|-----:|:--|
| ​        | ​ |            December 31, |   |      | ​ |    As of December 31, |   |      |   |
| ​        |   |                    2024 |   | 2023 |   |                  2024 |   | 2023 |   |
| ​        |   | % of operating expenses |   |      |   | % of accounts payable |   |      | ​ |
| Vendor A |   |                      62 | % |   33 | % |                    43 | % |   40 | % |
| Vendor B |   |                       1 | % |   14 | % |                     2 | % |    — | ​ |
| Vendor C |   |                       3 | % |    8 | % |                     8 | % |   10 | % |
| Vendor D |   |                       — |   |    — |   |                     — |   |   19 | % |
| ​        |   |                      66 | % |   55 | % |                    53 | % |   69 | % |

The Company’s preclinical studies and clinical trials and testing could be adversely affected by a significant interruption in the supply chain from its significant suppliers.

Cash and Cash Equivalents

The Company considers all highly liquid investments, with an original maturity of three months or less, to be cash equivalents. Cash equivalents include amounts held in money market funds in the amount of $ million and $ million as of December 31, 2024 and 2023, respectively.

The Company recorded interest income on its cash equivalents of $ million for the year ended December 31, 2024 on its statements on operations. The Company recorded interest income of $ million on its cash equivalents and previously outstanding short-term investments during the year ended December 31, 2023 on its statements of operations. The interest income recorded during the year ended December